Integra LifeSciences reported a 2.4% increase in first-quarter 2026 revenues to $391.9 million, driven by strong demand in tissue reconstruction and neurosurgery products. Adjusted earnings per share rose to $0.54 from $0.41 last year, while GAAP net loss narrowed significantly. The company reaffirmed its full-year revenue guidance of $1.662-$1.702 billion and raised adjusted EPS guidance to $2.40-$2.50, citing improved operational execution and supply reliability. New CEO Stuart Essig highlighted progress in manufacturing and product launches, with confidence in meeting full-year targets.
Investors who sold Activision Blizzard stock between January 18, 2022, and October 13, 2023, have until June 30, 2026, to apply to be lead plaintiffs in a class action lawsuit. The suit alleges that Activision Blizzard and its board made false and mi...
Defiance ETFs has introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed to provide twice the inverse daily performance of SpaceX stock (SPCX). This ETF targets active traders seeking short-term bearish exposure to SpaceX, a leadin...
Defiance ETFs introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed to provide investors with double inverse exposure to SpaceX's daily stock price movements. This ETF aims to deliver -200% of SpaceX's daily returns, allowing inve...
Defiance ETFs introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed for active traders seeking double inverse daily exposure to SpaceX stock. The ETF aims to deliver -200% of SpaceX's daily price movements, allowing investors to b...
Defiance ETFs has introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed for active traders seeking amplified daily inverse exposure to SpaceX stock. This ETF aims to deliver -200% of SpaceX's daily price movements, allowing invest...
